BPGbio Appoints Sheikh Dr. Khalid Bin Jabor Al Thani As Executive In Residence To Guide Strategic Programs And Corporate Development

BPGbio, Inc., a biology-first, AI-powered, clinical-stage biopharmaceutical company specializing in mitochondrial medicine and protein homeostasis, announced the appointment of Sheikh Dr. Khalid Bin Jabor Al Thani as Executive in Residence. Sheikh Dr. Khalid Bin Jabor Al Thani is an internationally recognized leader in cancer care, prevention, and patient advocacy. As Founder and Chairman of the Qatar Cancer Society, he has led initiatives to raise awareness, promote early detection, and develop public–private partnerships that have improved patient outcomes across the Gulf region and beyond. 

He currently serves as Vice President of the International Coalition for Cancer Patients (ICPC) and Chair of its Middle Eastern Coalition, connecting global stakeholders to address gaps in cancer care, access, and innovation. The ICPC, established over 40 years ago, is the world’s largest and oldest international cancer organization, representing more than 1,180 member organizations across 172 countries. Sheikh Dr. Khalid has also held senior leadership roles within Qatar’s healthcare system, including Undersecretary for the Ministry of Public Health and Vice Chairman of the National Health Authority, and served as Chair of the Board of Trustees at the University of Calgary in Qatar.

In his role at BPGbio, Dr. Al Thani will advise the company’s senior leadership and Board of Directors on global precision oncology initiatives, AI-driven biology innovation, and strategic expansion in the EU, Latin America, MENA, and Asia-Pacific regions. He will collaborate with the Scientific Advisory Board to advance BPGbio’s pipeline, including its lead asset BPM 31510 for glioblastoma multiforme (GBM), with a Phase 2b readout expected in mid-2026, as well as other aggressive solid tumors, mitochondrial disorders, and rare diseases.

Dr. Al Thani emphasized the importance of combining AI, patient biology, and global collaboration to accelerate the development of impactful therapies. He noted that BPGbio’s NAi platform and BPM 31510 program, which targets aggressive solid tumors, align closely with his mission of improving cancer outcomes through innovation and speed to market.

Prof. Chas Bountra, Chair of BPGbio’s Scientific Advisory Board, highlighted Dr. Al Thani’s extensive vision in global healthcare and oncology, noting that his guidance will be critical in advancing BPGbio’s clinical pipeline and strategic initiatives. Madappa N. Kundranda, Chief of Cancer Medicine at Banner MD Anderson Cancer Center, also praised Dr. Al Thani’s global and precision medicine expertise, stating it will enhance the company’s likelihood of success.

BPGbio’s pipeline includes mid- and late-stage oncology programs and treatments for rare childhood diseases linked to mitochondrial disorders. Its lead clinical program, the BPM 31510 franchise, is a first-in-class lipid conjugate nanotherapy targeting mitochondrial metabolism, currently in Phase 2b trials for GBM and being prepared for a registrational trial in Primary CoQ10 Deficiency (PCQD).

Niven R. Narain, Ph.D., President and CEO of BPGbio, stated that Dr. Al Thani’s appointment marks a major step in expanding BPGbio’s global presence. He emphasized that Dr. Al Thani’s deep knowledge of the Middle Eastern healthcare landscape, coupled with his international influence in oncology and patient advocacy, will help accelerate partnerships, enhance patient impact, and drive shareholder value as BPGbio advances its biology-driven medicine platform.